NewLimit vs BioNTech
Side-by-side comparison of AI visibility scores, market position, and capabilities
Raised $130M Series B (Kleiner Perkins) + $45M from Eli Lilly at $1.62B valuation. First demonstrated restoration of youthful killing function in aged human CD8 T cells.
About
NewLimit is a longevity biotechnology company that demonstrated the first-ever restoration of youthful killing function in aged human CD8 T cells using transcription factor payloads — a major biological milestone with implications for cancer immunotherapy and immune aging. The company raised $130 million in Series B financing led by Kleiner Perkins, followed by $45 million in additional financing from Eli Lilly at a $1.62 billion valuation, with clinical studies in planning.
German mRNA pioneer co-developed COVID-19 vaccine with Pfizer; 20+ clinical programs in oncology and infectious disease; pivoting to mRNA cancer immunotherapies with BNT111 melanoma vaccine evaluated in combination with Regeneron's cemiplimab as key pipeline asset.
About
BioNTech SE was founded in 2008 in Mainz, Germany by Ugur Sahin, Ozlem Tureci, and Christoph Huber with a mission to harness the immune system for individualized cancer treatment. The company pioneered individualized neoantigen-specific immunotherapy and mRNA-based therapeutic approaches before co-developing the world's first authorized mRNA vaccine with Pfizer during the COVID-19 pandemic.\n\nBioNTech's pipeline spans over 20 clinical programs in oncology, infectious disease, and autoimmune conditions. Key assets include BNT111, an mRNA cancer vaccine for melanoma evaluated in combination with Regeneron's cemiplimab, as well as a suite of CAR-T, bispecific antibody, and mRNA-encoded cytokine programs. The company manufactures mRNA therapies at scale through its BioNTainer modular facilities deployable to emerging markets.\n\nBioNTech generated approximately €2.4 billion in revenue in 2024 and holds a robust cash position exceeding €17 billion, enabling sustained R&D investment. The company is recognized as one of the most pivotal biotech success stories of the 21st century, combining deep immunology science with scalable mRNA manufacturing to pursue a world where cancer is a manageable disease.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.